Novartis AG (NYSE:NVS) Expected to Earn Q3 2025 Earnings of $1.98 Per Share

Novartis AG (NYSE:NVS) – Analysts at Zacks Research decreased their Q3 2025 earnings per share (EPS) estimates for shares of Novartis in a report issued on Monday, April 22nd. Zacks Research analyst E. Bagri now anticipates that the company will earn $1.98 per share for the quarter, down from their previous estimate of $1.99. The consensus estimate for Novartis’ current full-year earnings is $7.15 per share.

NVS has been the topic of several other reports. Morgan Stanley began coverage on Novartis in a research note on Tuesday, January 23rd. They issued an “equal weight” rating and a $114.00 price objective on the stock. BMO Capital Markets raised their price objective on Novartis from $114.00 to $116.00 and gave the company a “market perform” rating in a research note on Wednesday. Three investment analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $115.00.

Novartis Stock Performance

NYSE:NVS opened at $99.06 on Wednesday. The stock’s 50-day simple moving average is $97.92 and its 200 day simple moving average is $98.99. The firm has a market capitalization of $202.48 billion, a PE ratio of 13.37, a price-to-earnings-growth ratio of 1.58 and a beta of 0.54. The company has a quick ratio of 0.93, a current ratio of 1.15 and a debt-to-equity ratio of 0.39. Novartis has a twelve month low of $92.19 and a twelve month high of $108.78.

Novartis (NYSE:NVS) last released its quarterly earnings data on Tuesday, January 30th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.11). The business had revenue of $11.42 billion during the quarter, compared to analyst estimates of $11.69 billion. Novartis had a net margin of 31.33% and a return on equity of 31.12%. During the same period last year, the business earned $1.51 earnings per share.

Hedge Funds Weigh In On Novartis

Several large investors have recently bought and sold shares of the company. Wellington Management Group LLP raised its position in Novartis by 1.2% in the fourth quarter. Wellington Management Group LLP now owns 4,746,599 shares of the company’s stock valued at $479,264,000 after purchasing an additional 54,683 shares during the last quarter. Principal Financial Group Inc. raised its position in shares of Novartis by 2.1% during the third quarter. Principal Financial Group Inc. now owns 2,539,265 shares of the company’s stock worth $258,650,000 after acquiring an additional 51,391 shares during the last quarter. Envestnet Asset Management Inc. raised its position in shares of Novartis by 50.4% during the third quarter. Envestnet Asset Management Inc. now owns 2,049,901 shares of the company’s stock worth $208,803,000 after acquiring an additional 686,847 shares during the last quarter. Grantham Mayo Van Otterloo & Co. LLC raised its position in shares of Novartis by 167.6% during the third quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 1,827,263 shares of the company’s stock worth $186,125,000 after acquiring an additional 1,144,307 shares during the last quarter. Finally, Fisher Asset Management LLC raised its position in shares of Novartis by 2.4% during the fourth quarter. Fisher Asset Management LLC now owns 1,442,003 shares of the company’s stock worth $145,599,000 after acquiring an additional 33,791 shares during the last quarter. 13.12% of the stock is currently owned by institutional investors.

Novartis Increases Dividend

The company also recently announced an annual dividend, which was paid on Thursday, March 7th. Shareholders of record on Friday, March 8th were given a $3.7772 dividend. The ex-dividend date of this dividend was Thursday, March 7th. This is an increase from Novartis’s previous annual dividend of $3.47. This represents a yield of 3.1%. Novartis’s dividend payout ratio (DPR) is currently 32.79%.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.